Apnimed (APMD) Stock Analysis
NASDAQHealthcareBiotechnology
What Apnimed does
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Key metrics
ETFs linked to APMD
Broad-market and Healthcare sector ETFs an investor holding Apnimed is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how APMD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze APMD in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Apnimed?
- Apnimed trades under the ticker APMD on NASDAQ.
- Which exchange is APMD listed on?
- APMD is listed on NASDAQ.
- What sector does Apnimed operate in?
- Apnimed is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze APMD in a portfolio?
- PortView shows APMD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.